AN2 Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Business Wire

01-30

MENLO PARK, Calif., January 29, 2025--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform, today announced that Eric Easom, Co-Founder, Chairman, President and CEO, will present at the Oppenheimer 35^th Annual Healthcare Life Sciences Conference.

Details of the event are as follows:

Oppenheimer 35^th Annual Healthcare Life Sciences Conference (virtual)

Eric Easom, Co-Founder, Chairman, President and CEO will provide a corporate overview on Wednesday, February 12, 2025 at 3:20pm ET.

A webcast of the presentation can be accessed on the Investors section of the AN2 Therapeutics website at www.an2therapeutics.com. An archived replay will be available for at least 30 days following the presentation.

About AN2 Therapeutics, Inc.

AN2 Therapeutics, Inc. is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. AN2 has a pipeline of boron-based compounds in development for Chagas disease, NTM, and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology. For more information, please visit our website at www.an2therapeutics.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250129335824/en/

Contacts

COMPANY CONTACT:
Lucy O. Day
Chief Financial Officer
l.day@an2therapeutics.com

INVESTOR AND MEDIA CONTACT:
Anne Bowdidge
ir@an2therapeutics.com

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2507982665"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2507982665\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2507982665?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-01-30 05:00","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2507982665","market":"us","top_or_hot":-1,"title":"AN2 Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference","media":"Business Wire","content":"<html><body>\n<figure>\n<img border=\"0\" height=\"270\" src=\"https://s1.yimg.com/uu/api/res/1.2/AqcKt1AjXJDKmQoBcauXJA--/cT03NTthcHBpZD15dmlkZW9mZWVkczs-/https://media.zenfs.com/en/business-wire.com/0a09f1638c7a1f97682541130640ca4e\" title=\"\" width=\"480\"/>\n<figcaption></figcaption>\n</figure>\n<p><b>MENLO PARK, Calif., January 29, 2025</b>--(BUSINESS WIRE)--<a href=\"https://laohu8.com/S/ANTX\">AN2 Therapeutics, Inc.</a> (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform, today announced that Eric Easom, Co-Founder, Chairman, President and CEO, will present at the Oppenheimer 35<sup>th</sup> Annual Healthcare Life Sciences Conference.</p>\n<p>Details of the event are as follows:</p>\n<p>Oppenheimer 35<sup>th</sup> Annual Healthcare Life Sciences Conference (virtual)</p>\n<ul>\n<li>Eric Easom, Co-Founder, Chairman, President and CEO will provide a corporate overview on Wednesday, February 12, 2025 at 3:20pm ET.</li>\n</ul>\n<p>A webcast of the presentation can be accessed on the Investors section of the AN2 <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> website at www.an2therapeutics.com. An archived replay will be available for at least 30 days following the presentation.</p>\n<p><b>About AN2 Therapeutics, Inc.</b></p>\n<p>AN2 Therapeutics, Inc. is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. AN2 has a pipeline of boron-based compounds in development for Chagas disease, NTM, and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology. For more information, please visit our website at www.an2therapeutics.com.</p>\n<p><span>View source version on businesswire.com: </span><span>https://www.businesswire.com/news/home/20250129335824/en/</span></p>\n<p><b>Contacts</b></p>\n<p><b>COMPANY CONTACT: </b><br/>Lucy O. Day<br/>Chief Financial Officer<br/>l.day@an2therapeutics.com<br/><br/><br/></p>\n<p><b>INVESTOR AND MEDIA CONTACT: </b><br/>Anne Bowdidge<br/>ir@an2therapeutics.com<br/><br/></p></body></html>","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AN2 Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAN2 Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-01-30 05:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/an2-therapeutics-present-oppenheimer-35th-210000880.html><strong>Business Wire</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>MENLO PARK, Calif., January 29, 2025--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics ...</p>\n\n<a href=\"https://finance.yahoo.com/news/an2-therapeutics-present-oppenheimer-35th-210000880.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":null,"symbol_name":null,"start_time":0,"source_url":"https://finance.yahoo.com/news/an2-therapeutics-present-oppenheimer-35th-210000880.html","article_id":"2507982665","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2507982665","pubTimestamp":1738184400,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"MENLO PARK, Calif., January 29, 2025----AN2 Therapeutics, Inc. , a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform, today announced that Eric Easom, Co-Founder, Chairman, President and CEO, will present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference.Eric Easom, Co-Founder, Chairman, President and CEO will provide a corporate overview on Wednesday, February 12, 2025 at 3:20pm ET.","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{},"translate_title":"AN2 Therapeutics将出席奥本海默第35届年度医疗保健生命科学会议","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ANTX":0.9,"HCSG":1,"LENZ":1,"OPY":1},"content_text":"MENLO PARK, Calif., January 29, 2025--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform, today announced that Eric Easom, Co-Founder, Chairman, President and CEO, will present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference.\nDetails of the event are as follows:\nOppenheimer 35th Annual Healthcare Life Sciences Conference (virtual)\n\nEric Easom, Co-Founder, Chairman, President and CEO will provide a corporate overview on Wednesday, February 12, 2025 at 3:20pm ET.\n\nA webcast of the presentation can be accessed on the Investors section of the AN2 Therapeutics website at www.an2therapeutics.com. An archived replay will be available for at least 30 days following the presentation.\nAbout AN2 Therapeutics, Inc.\nAN2 Therapeutics, Inc. is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. AN2 has a pipeline of boron-based compounds in development for Chagas disease, NTM, and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology. For more information, please visit our website at www.an2therapeutics.com.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20250129335824/en/\nContacts\nCOMPANY CONTACT: Lucy O. DayChief Financial Officerl.day@an2therapeutics.com\nINVESTOR AND MEDIA CONTACT: Anne Bowdidgeir@an2therapeutics.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}